{
    "organizations": [],
    "uuid": "3eaa33094d7f1af1ae15feb0236f09038138b32e",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-psivida-submits-new-drug-applicati/brief-psivida-submits-new-drug-application-for-durasert-three-year-treatment-for-posterior-segment-uveitis-to-the-u-s-fda-idUSASB0C041",
    "ord_in_thread": 0,
    "title": "BRIEF-pSivida Submits New Drug Application For Durasert Three-Year Treatment For Posterior Segment Uveitis To The U.S. FDA",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - pSivida Corp:\n* PSIVIDA SUBMITS NEW DRUG APPLICATION (NDA) FOR DURASERT™ THREE-YEAR TREATMENT FOR POSTERIOR SEGMENT UVEITIS TO THE U.S. FDA\n* PSIVIDA CORP - ‍SUBMITTED NDA TO U.S. FDA FOR DURASERT THREE-YEAR TREATMENT FOR POSTERIOR SEGMENT UVEITIS​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T22:05:00.000+02:00",
    "crawled": "2018-01-09T17:05:58.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "psivida",
        "corp",
        "psivida",
        "submits",
        "new",
        "drug",
        "application",
        "nda",
        "treatment",
        "posterior",
        "segment",
        "uveitis",
        "fda",
        "psivida",
        "corp",
        "nda",
        "fda",
        "durasert",
        "treatment",
        "posterior",
        "segment",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}